SPECIAL ALERT

	TOP 4 REASONS = TO BUY WSCH

The products and medical therap= ies developed by WSCH represent possibly the most important breakthroug= h in the field of Dermatology in the last fifty years.
2.	WSCH anticipates FDA approval on seven over-the-counter= products within the next year, which will provide significant revenue in = the retail drug market.
3.	WSCH has experienced a= success rate of 90% during clinical studies, completely eliminatin= g skin disease from 90% of all patients treated.
4.	By year five, WSCH plans to have annualized revenue over $525 millio= n and over $125 million in EBIT. This does not take into = account income from OTC products which will be substantial. = ;
	= PROJECT= IONS, OBJECTIVES AND STATISTICS
&= nbsp; &nb= sp; = ; &= nbsp; &nb= sp; = ; Over a five year period, AISC (WSCH's subsidiary) plans to establi= sh 350 clinics in over 100 major population areas. The company= plans to hire over 150 medical doctors for these clinics, train over 1,00= 0 medical assistants and treat over 2,000,000 patients. Also by yea= r five, WSCH plans to have annualized over $525 million in revenue and = over $125 million in EBIT. This does not take into account income from= OTC products which will be substantial. As of 1991, there w= ere approximately 14 million chronic acne and eczema patients annua= lly in the United States, with the highest percentage between 18 to 4= 4 years of age. The actual number of patients with any type of acne&n= bsp;Is significantly higher. Seven billion dollars is spent a= nnually on dermatological pharmaceutical products for these disor= ders. In 1994, the teen population reached 25 million= During the next decade, it will grow at nearly twice the rate of= the overall population (according to U.S. Census Bureau pro= jections). Acne patients are primarily teenagers, whereas eczema= patients range from infants to the elderly.

SYMBOL:	= ; WSCH
= &n= bsp; CURRENT PRICE:	<= /font>$0.059
&nb= sp; 52 WEEK HIGH:	$27.50
52 WEEK LOW:	= $0.0= 56

COMPANY BACKGROUND

Wasatch Pharmaceutical, Inc. is a fourteen ye= ar old company with a record of outstanding achievements in the field of D= ermatology. Dermatology. Under the name of its subsidiary, American I= nstitute of Skin Care (AISC), Wasatch has operated two prototype cl= inics for the last five years where the products and medical therapies hav= e been tested and proven on hundreds of patients. The Company's activities= have been centered on research in the area of serious skin diseases. A concurrent discovery and benefit = is WSCH's dramatic success in the area of skin rejuvenation.

Seeing the high growth potential from major funding, WSC= H elected to become a public company less than two years ago.

Wasatch's major successes in the area o= f skin diseases include:

Cystic Acne, Ec= zema, Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea= and less prevalent skin diseases.

Inte= restingly, these skin disorders account for more than 70% of all busine= ss in the field of dermatology for which there are very few (if any) s= afe, effective therapies like those developed by Wasatch.

Because the therapies developed by Wasatch domina= te this area of medicine, WSCH has elected to market its products via = company-owned clinics throughout the United States. This decision has= resulted in the establishment of two research clinics in Utah for = the purpose of implementing procedures within the clinics pursuant to test= ing and confirming the results that were achieved in past clinical trials.= Due to its success rate of 90% on hundreds of patients over a f= ive year period, WSCH's clinics are now on line with insurance provide= rs independent of HMOs. Efforts to establish Preferred Providership status= with HMOs are presently being pursued.

MURRAY, Utah--(BUSINESS WIRE)--Nov. 27, 2001--Wasatch Ph= armaceutical Inc. (OTCBB:WSCH - news)= CEO Gary Heesch announced today a marketing campaign directed to physicia= ns. A direct link has been established on a physician recruiting Web site = making available therapies for the treatment of cystic acne, acne, follicu= litis and skin rejuvenation. Physicians will find the benefits of these tr= eatment therapies by logging on to the "X Acne" link at the P= hysician Search website. This physician search Web site typically rece= ives over 200,000 hits per month. Mr. Heesch reminded, "Our tr= eatment therapy products are also available via the AISC Online Store.&quo= t;

These skin treatmen= t products come in kit form providing a 90-day supply to patients for the = full treatment program. Included in the kit is an instructional video on t= he treatment therapy allowing the patient to use these products in their h= ome. The therapies, when used as instructed, achieve a success rate of = eradication in excess of 90% with no side effects of any consequence. = Previously, these therapies and associated products were only available th= rough the two prototype clinics in Utah. The availability of these product= s will open the way for family practitioners, pediatricians, internists an= d other primary care physicians to retain their patients under their care = during the treatment of these common skin disorders. The benefit to ins= urance providers is the potential to save millions of dollars in reimburse= ment costs by freeing the physician and the patient from ongoing treatment=

In the coming year, s= ix additional therapies will be made available for a broad range of sk= in disorders that are badly in need of successful therapies.

= Gary Heesch also announced the listing of W= asatch Pharmaceutical stock on the Frankfurt and Berlin Exchanges in Ge= rmany. Active trading on these exchanges will take place upon the comp= letion of a research report in Germany. Said Mr. Heesch, "We feel thi= s is a significant event as Wasatch will gain wider exposure as a l= eader in dermatology and will put buying pressure on its stock t= o reflect the true value of a company that has committed years = of research and development of products that allow people with serious ski= n disorders to live normal and more productive lives."

<= font face=3DArial size=3D1>There may be forward-looking statements in t= his release. Investors are cautioned that such forward-looking statements = involve risks and uncertainties, including, without limitation, continued = acceptance of the Company's products, increased levels of competition, new= products introduced by competitors, changes in the rates of subscriber ac= quisition and retention, and other risks detailed from time to time in the= Company's periodic reports filed with the Securities and Exchange Commiss= ion.

Wasatch Pharmaceutical Inc. Announ= ces a New Physician Marketing Campaign and Listing On German Stock Exchang= es